Extended-release sodium oxybate for children with narcolepsy
Part of Brain & nervous system, Mental health clinical trials.
This trial tests an extended-release medicine (sodium oxybate) to see if it helps children with narcolepsy type 1 feel less sleepy during the day. It is only for children who are seen at the Stanford Sleep Clinic and have a clear diagnosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your child) are being treated by a doctor at the Stanford Sleep Clinic.
- Your child has a confirmed diagnosis of narcolepsy type 1 (based on specific tests or symptoms).
- You (the parent or guardian) and your child agree to take part in the study.
- Your child is on a steady dose of their current medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called TAK-360 to help adults with narcolepsy type 1 (a condition that causes extreme daytime sleepiness and sudden muscle weakness called cataplexy) feel more alert during the day. The goal is to see if this treatment is safe and effective for managing narcolepsy symptoms.
This trial tests a new medication called TAK-861 for people with narcolepsy type 1 (NT1), which causes sudden muscle weakness (cataplexy) and extreme daytime sleepiness. The study aims to see if TAK-861 can help reduce these symptoms.
This trial tests whether low-dose sodium oxybate can improve symptoms in adults with idiopathic hypersomnia, a condition that causes excessive sleepiness. You’d likely be asked to pause this standard treatment briefly while baseline testing is completed, and you’d use reliable contraception during and after the study drug.
This study tests whether a new medication called ALKS 2680 can help people with narcolepsy type 1 stay more awake and alert during the day. Narcolepsy type 1 is a neurological condition where people fall asleep unexpectedly and may experience sudden muscle weakness.
This study tests an investigational drug called ALKS 2680 for people with narcolepsy type 2, a condition that causes excessive daytime sleepiness without sudden muscle weakness. The goal is to see if the drug is safe and helps reduce daytime sleepiness.
This study tests whether taking the sleep medicine Xywav two times each night is safe and helps control symptoms better than a placebo. People with narcolepsy or idiopathic hypersomnia may join, including those who have not tried oxybate medicines before.
Hear when a new Narcolepsy Type 1 (NT 1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.